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Anal Intraepithelial Neoplasia (AIN) is an increasingly common condition for which the best treatment
has not been well established. Traditional management was based on a ‘watch and wait’ strategy, but as
the natural history of AIN and its progression to anal cancer is becoming better understood, more active
treatment strategies are warranted. A Best Evidence Topic in Surgery was written according to a struc-
tured protocol to address the question whether treatment is indicated in patients with AIN. A total of 169
papers were identiﬁed using the deﬁned search criteria. This included only one randomised controlled
trial. Case series were therefore also included to help answer the question. The details of the papers were
tabulated including relevant outcomes and study weaknesses. We conclude that treatment of high grade
AIN, particularly in high risk groups is recommended to try to avoid progression to anal cancer. Treat-
ment options that have shown some beneﬁt include topical use of imiquimod cream or ablation directed
by high resolution anoscopy.
 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
A best evidence topic was constructed according to a struc-
tured protocol. This is fully described in a previous publication in
the IJS.12. Clinical scenario
A GP refers a 44 year old HIV positive male, currently on anti-
retroviral treatment, to your colorectal outpatient clinic. The
patient is complaining of anal irritation and some rectal bleeding.
Examination reveals a small anal wart which you swab and
the sample comes back showing high grade dysplasia. You
wonder how best to proceed with the management of this pa-
tient and whether any intervention is required to improve his
outcome.3. Three-part question
In patients with AIN, does treatment reduce their risk of pro-
gression to anal cancer?thmead Road, Westbury-on-
; fax: þ44 2392286000.
hard).
ciates Ltd. Published by Elsevier Lt4. Search strategy
Medline 1966-November 2011 using the Pubmed interface for
the terms: Anal AND Intraepithelial AND Neoplasia AND Treatment
[All Fields]. Limits applied to papers in English and to human
studies only.
5. Search outcome
A Pubmed Medline search for ‘Anal’ AND ‘Intraepithelial’ AND
‘Neoplasia’ and limits of ‘English’ and ‘Humans’ identiﬁed 355 pa-
pers. When the term ‘Treatment’ was added to the search terms,
this reduced to 184 results. Of these, 74 were irrelevant and a
further 40 were about AIN but not its treatment. 44 papers were
from more than 10 years ago and a further 7 were case studies of
single patients and these were also excluded. This left only one
randomised controlled trial and 18 case series (both prospective
and retrospective). Of these 18 papers, those reporting a minimum
of 6 months follow up and at least 10 patients were selected, giving
a total of 4 case series (Table 1).
6. Discussion
The termanal intraepithelial neoplasia (AIN) describes dysplastic
changes in the squamous epitheliumwhich arenowwidely believed
to be the precursor to squamous cell carcinoma (SCC) of the anus.
AIN can be categorised as Grades 1, 2 or 3, with Grade 1 oftend. All rights reserved.
Table 1
Best evidence papers.
Author, date and
country
Patient group Study type (level of evidence) Outcomes Key results Comments
Fox,5 London,
Sept 2010
64 HIV positive MSM
on HAART, with HGAIN.
Intervention
group e 28 patients,
self application of
imiquimod
cream, 3 per week
for 4 months.
Control
group e 25 patients,
placebo cream.
Double blinded randomised
controlled trial
(Level 2)
Improvement in
Treatment Group
4/28 (14%) resolved
completely and 8/28 (28%)
downgraded to low
grade AIN.
This paper beneﬁts from being the
only randomised controlled trial
for treatment of AIN. It also
has a reasonable duration of
follow up (36 months). It
concludes that there is some
beneﬁt from imiquimod tx for
HIV patients with HGAIN. No
evidence yet if it reduces
progression to SCC.
The crossover nature of the study
makes it very unclear & difﬁcult to
follow however, making it difﬁcult to
understand which patients progressed to
second and third round treatments.
Improvement in
dysplasia e second &
third round treatments
14/16 non responders in
tx group then had further
tx: 3 (21%) resolved,
3 (21%) downgraded,
8 (58%) persisted.
21 non responders
(across both groups)
then underwent
imiquimod tx
for 4 months.
5/21 (24%) resolved
& 4/21 (19%)
downgraded.
Improvement in dysplasia
Placebo group
1/25 (4%) resolved.
Other outcomes 11 patients dropped out.
2 resolved spontaneously.
2 developed SCC.
Wieland,7 Cologne,
Germany, Nov 2006
28 HIV positive MSM with
conﬁrmed AIN
(mixture of AIN 1, 2 & 3).
Intervention: Imiquimod cream if
perianal (23/28) and suppositories
if intra-anal (5/28), 3 per week
for 16 weeks.
F/up every 4e6 weeks.
6 patients non compliant.
Prospective study
(Level 3)
Improvement in dysplasia
Treatment Group
17/22 compliant pts
showed histological
clearance
at end of treatment.
Further 3 were clear at
end of f/up but 3 initial
responders developed
recurrent AIN.
Showed good initial response rates
and improvement in HPV type and
DNA load. No signiﬁcant side effects
documented.
This paper documents short follow
up (mean 9.5 months) e recurrences
documented from w1 yr in other
papers. Only small numbers of
patients with no control group.
6 patients non compliant e 4 showed
no improvement and 2 progressed
from LGAIN to HGAIN.
Other outcomes Mean no. of HPV
types reduced
from 4.7 to 2.6.
Signiﬁcant reduction
in HPV DNA load (p < 0.001)
initially, increased
again when treatment stopped.
Chang,8 California,
April 2002
37 men with high grade AIN.
Of these 29 were HIV positive
and 8 HIV negative.
Intervention: Electrocautery
ablation of lesions directed by
HRA & staining
Prospective case series
(Level 3)
Improvement in
dysplasia e HIVþ
6/29 (21%) HIV positive
patients were clear of HGAIN at
mean 12 months. Mean
follow up 28.6 months.
Good response in HIV negative patients.
No patients progressed to SCC during
follow up period.
Very poor response in HIV positive
patients e may need multiple treatments.
No signiﬁcant complications reported
(no stenosis/abscess/incontinence) but
post op pain was signiﬁcant problem.
Improvement in
dysplasia e HIV
8/8 (100%) of the HIV
negative patients were clear
of HGAIN at mean
follow up 32.3 months.
Other outcomes 16 of 29 (55%) reported
signiﬁcant post op pain
lasting mean 2.9 weeks
(continued on next page)
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REVIEWreferred to as Low Grade (LGAIN) and 2 and 3 grouped together as
High Grade (HGAIN). The reported incidence of HGAIN is 0.45 per
100,000population, but prevalence ismuchhigher in ‘at risk’ groups
such as HIV positive menwho have sex with men (MSM) (52%) and
immunosuppressed renal transplant patients (5%).2 It is nowwidely
accepted that AIN is a pre-malignant condition, and as such con-
cerns about progression to malignancy have prompted investi
gations into treatment options for AIN. Traditional excisional sur-
gery has been associated with very high rates of morbidity3 and
there has therefore been an increasing focus on the efﬁcacy of less
invasive treatment options for this condition.
To date there has only been one double-blinded randomised
controlled trial looking at medical treatment of AIN. This trial used
imiquimod, a drugwhich has been shown to be a useful treatment in
other skin conditions including actinic keratoses, basal and squamous
cell carcinomasof theskinandgenitalwarts.4 Foxetal.5 compared the
use of topical imiquimod cream3 times perweek for 16weekswith a
placebo cream. Over a median follow up of 33 months, and up to 3
rounds of treatment, they demonstrated that 51% of their patients
showed some response (either resolution or downgrading of their
HGAIN). They concluded that imiquimod is a safe and well tolerated
treatment and may be a useful adjunct in the treatment of AIN. This
paper has the advantage of being the only placebo controlled trial
identiﬁed for AIN, but the results are not particularly convincing and
the raw data in the paper are very difﬁcult to follow.
With respect to analysing the results from case series, it is
important to benchmark these results against outcomes of un-
treated AIN. Although it is now widely accepted that AIN is a pre-
malignant condition, the actual rate of progression to SCC are not
well documented. In the largest published series, Watson et al.6
described an observational study of 72 patients with untreated
AIN. Of these patients, eight (11%) progressed to SCC over an eight
year period. They also noted that 25 of their 72 (35%) patients
regressed in grade of AIN.
Wieland et al.7 examined the use of imiquimod in 28 HIV pos-
itive menwith AIN. Of 22 compliant patients, 17 (77%) were clear of
AIN at the end of a mean follow up of 9.5 months. They also re-
ported a reduction in themean number of HPV types from 4.7 to 2.6
per person and no progression to SCC. Although this was a high
percentage response rate it is probably too short a duration of
follow up as the paper byWatson et al.6 reported high incidences of
recurrent disease beginning to occur at 12 months. The paper also
considered a mixture of HGAIN and LGAIN which may explain the
high response rates as LGAIN often resolves spontaneously.
Furthermore, the high rate of non-compliance (20%) is discouraging
for those wishing to use imiquimod more widely.
Another technique that has been investigated for the treatment of
AIN is electrocautery ablation. This was described in 2002 by Chang
et al.8 as a surgical procedure tobeperformed in the operating theatre
under IV sedationwith a perianal block. They looked at 37 menwith
HGAIN, 29 of whomwere HIV positive and 8 HIV negative. They used
acetic acid and iodine solution with high resolution anoscopy (HRA)
to identify lesions and then ablated them by cauterisation. They
showed full and persistent resolution of HGAIN in all 8 HIV negative
patients. However 23 (79%) of the 29 HIV positive patients showed
persistent or recurrent disease at a mean of 12 months. 6 of these
patients underwent further treatment, of whom 4 had recurred by 6
months. They reported no major complications (speciﬁcally no ab-
scesses, stenosis or incontinence) and no patients progressed to SCC
over an average follow up of 30 months. However, all the patients
described perianal irritation and erythema, and 16 patients reported
signiﬁcant pain lasting a mean of 2.9 weeks.
The technique of ablation using HRA was further developed in
2005 by Goldstone et al.3 They used infra-red coagulation to ablate
thedysplastic lesions andperformed the treatments in the outpatient
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REVIEWsetting under local anaesthetic. They performed a retrospective re-
view of 68 HIV positive patients with high grade but non-bulky or
circumferential disease who had been treated with infra-red coagu-
lation between 1999 and 2005. Many patients had multiple sites of
dysplasia and in total 165 lesions were treated over a 6 year period.
After up to 3 rounds of treatment, 48/68 (70%) of patients had
responded and were clear of disease. There were no signiﬁcant
complications and none of the patients progressed to SCC over the
minimum follow up of 6months. The authors concluded that this is a
safe treatment to be performed in outpatients and is effective in
improvingHGAIN and thereby reducing progression to SCC. They did,
however, document high early recurrence rates (64% after the ﬁrst
roundof treatment), and the need for repeated interventions inmany
cases. In 20079 they performed a further retrospective review looking
at 75 HIV negative patients with HGAIN who had also been treated
with HRA and infra-red ablation. In these patients they showed 79%
clearance at the end of 3 rounds of treatment. 16 of these patients
were lost to follow up so their data are incomplete. They also
acknowledge that thenaturalhistoryofAINand itsprogression to SCC
is not fully known, so it is impossible to extrapolate their results into
estimating numbers of cancers prevented, which is the whole aim in
the treatment of AIN.
These papers demonstrate that treatment of AIN is difﬁcult,
particularly in HIV positive patients where recurrence rates are very
high. Topical treatmentwith imiquimodandablative techniques have
been demonstrated to be safe and to have some beneﬁt in reducing
HGAIN. All of the paperswith intervention report rates of progression
to SCC that are much lower than the 11% observed by Watson et al.,
though this may be a product of insufﬁcient follow up in some cases.
Overall there is virtually no level 1 or 2 evidence in this area, and
muchmoreworkneeds to bedone, both comparing the treatments to
a placebo, and to one-another. One of the main factors limiting more
robust research is sample size. Even in specialist centres, the numbers
of patients seen and treated each year are very low and most of the
papers published are using data collected over 5e10 years. There is
also the question as towhether it is ethical to use a placebo treatment
for a randomized controlled trial for a condition that is believed to
progress to malignancy if left untreated. It would be very interesting
to see a multi-centre trial comparing treatment with imiquimod and
ablation or a combination of the two to see if one treatmentmodality
is demonstrably better. It seems clear that HIV negative patients
respond much better to treatment than HIV positive patients (0%
recurrence in HIV negative compared to 79% in HIV positive patients
for Chang et al.). There is also well documented spontaneous
regression of LGAIN (35%)5 but high rates of recurrence or persistence
inHGAIN. Future studies should aimtoparticularly target theseworse
prognosis groups. It shouldbenoted that a comprehensive andexpert
overview of the management of anal cancer, has recently been pub-
lished by a Standards Committee from the American Society of Colon
and Rectal Surgeons.10 Although this study focussed mainly on
squamous cell carcinoma, this paper also provided guidance on the
assessment and management of AIN. Unlike our review this paper
does not provide quantitative of the data on AIN but also concluded
that the best advice for AIN is based low or very low quality evidence.7. Clinical bottom line
While the evidence for the different treatment options for AIN is
weak, the consensus appears to be unanimous that some treatment
is required to prevent progression to SCC. The decision between
imiquimod and ablation under HRA may lie with local preference
and experience, but watchful waiting is no longer considered to be
a justiﬁable option. Particular care and close follow up should be
undertaken on the highest risk groups such as those HIV positive
patients with high grade AIN.
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